2024
Use of Mitotic Activity and the Size of Any Dedifferentiated Component for Risk Assessment in MDM2-Amplified Liposarcoma.
Wu H, Sukhanova M, Tang H, Lu X, Zhong M, Deshpande H, Pollack S, Laskin W, Alexiev B. Use of Mitotic Activity and the Size of Any Dedifferentiated Component for Risk Assessment in MDM2-Amplified Liposarcoma. Archives Of Pathology & Laboratory Medicine 2024 PMID: 39164013, DOI: 10.5858/arpa.2024-0098-oa.Peer-Reviewed Original ResearchAtypical lipomatous tumor/well-differentiated liposarcomaMDM2-amplified liposarcomasDedifferentiated componentDedifferentiated liposarcomaAdverse eventsMitotic countLocal recurrence statusMDM2 copy numberAssociated with adverse eventsLog-rank testOverall tumor volumeUnivariate logistic regressionChromosome 12q13-15Statistically significant associationPercentage of cellsTumor dimensionTumor volumeTumor sizeMDM2 proto-oncogeneClinicopathological characteristicsPathology reportsGrade 3Recurrence statusUnivariate analysisMultivariate regression model
2023
Clear cell chondrosarcoma: a review of clinicopathologic characteristics, differential diagnoses, and patient management
Alexiev B, Vormittag-Nocito E, Peabody T, Samet J, Laskin W. Clear cell chondrosarcoma: a review of clinicopathologic characteristics, differential diagnoses, and patient management. Human Pathology 2023, 139: 126-134. PMID: 37805864, DOI: 10.1016/j.humpath.2023.06.004.Peer-Reviewed Original ResearchConceptsClear cell chondrosarcomaDiagnosis of clear cell chondrosarcomaPrimary bone tumorsDiagnostic accuracy of core needle biopsyAccuracy of core needle biopsyBone tumorsRarest primary bone tumorsLocal recurrence rateAbundant clear cytoplasmCore needle biopsyRate of recurrenceYounger patient ageLow-grade chondrosarcomaSkeletally immature patientsMalignant cartilaginous neoplasmsDecades of lifeEpiphysis of long bonesLow diagnostic accuracyOperative resectionIncomplete excisionNeedle biopsyHistopathological diagnosisPatient ageRecurrence rateClinicopathological characteristics